# Quantum-Synaptic Immunotherapy Mapping Using Low-Frequency Electromagnetic Resonance and Machine Learning-Based Cytokine Forecasting

> **NCT07221565** · PHASE1,PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Truway Health, Inc.** · enrollment: 120 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus
- Rheumatoid Arthritis
- Multiple Sclerosis
- Autoimmune Diseases
- Chronic Inflammatory Syndromes
- Immune Dysregulation

## Interventions

- **DEVICE:** Low-Frequency Electromagnetic Resonance Therapy (LF-EMR)
- **DEVICE:** Sham Resonance Device (Inactive Control)
- **DRUG:** Low-Dose Naltrexone (LDN)

## Key facts

- **NCT ID:** NCT07221565
- **Lead sponsor:** Truway Health, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-10-23
- **Primary completion:** 2034-10-23
- **Final completion:** 2034-10-23
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07221565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07221565, "Quantum-Synaptic Immunotherapy Mapping Using Low-Frequency Electromagnetic Resonance and Machine Learning-Based Cytokine Forecasting". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07221565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*